Diagnostic assays for discriminating Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance are provided. The method comprises obtaining a biological sample from a subject in need thereof, performing an allele-specific polymerase chain reaction assay to determine in the biological sample a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2, and providing a report indicating whether delta C.sub.T value of the biological sample is less than a reference value, wherein the subject has Waldenstrom's Macroglobulinemia if the delta C.sub.T value is less than the reference value.

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (Degrons), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (Degrons), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (Degrons), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (Degrons), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.

##STR00001##

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt thereof, and the therapeutic uses of said compound. The present invention further provides a pharmaceutical composition comprising said compound.

##STR00001##

Disclosed is a compound of formula (I) and (II) or a pharmaceutically acceptable salt, prodrug, tautomer or stereoisomer, and solvate thereof. The compound can be applied to treatment of cancers and inflammations of mammals. Further disclosed are a preparation method for the compound of formula (I) and (II) and a pharmaceutical composition containing the compound.

##STR00001##

Disclosed is a compound of formula (I) and (II) or a pharmaceutically acceptable salt, prodrug, tautomer or stereoisomer, and solvate thereof. The compound can be applied to treatment of cancers and inflammations of mammals. Further disclosed are a preparation method for the compound of formula (I) and (II) and a pharmaceutical composition containing the compound.

##STR00001##

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.9, R.sup.10, Q, X, Y, Z, A, L, B, m, n and p are as defined herein. ##STR00001##